-
Tytuł:
-
Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
-
Autorzy:
-
Akaishi T; Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi 980-8574, Japan; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan. Electronic address: .
Himori N; Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takeshita T; Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Misu T; Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
Takahashi T; Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi 980-8574, Japan; Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Japan.
Takai Y; Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
Nishiyama S; Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
Fujimori J; Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Ishii T; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
Aoki M; Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
Fujihara K; Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima, Japan.
Nakazawa T; Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Nakashima I; Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
-
Źródło:
-
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Nov; Vol. 56, pp. 103222. Date of Electronic Publication: 2021 Aug 24.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Amsterdam] : Elsevier B. V.
-
MeSH Terms:
-
Neuromyelitis Optica*
Optic Neuritis*/drug therapy
Aquaporin 4 ; Autoantibodies ; Humans ; Myelin-Oligodendrocyte Glycoprotein
-
Contributed Indexing:
-
Keywords: Anti-aquaporin-4 antibody; Anti-myelin oligodendrocyte glycoprotein antibody; Multiple sclerosis; Optic neuritis; Visual outcome
-
Substance Nomenclature:
-
0 (Aquaporin 4)
0 (Autoantibodies)
0 (Myelin-Oligodendrocyte Glycoprotein)
-
Entry Date(s):
-
Date Created: 20210830 Date Completed: 20211216 Latest Revision: 20211216
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.msard.2021.103222
-
PMID:
-
34461572
-
Introduction: Optic neuritis (ON) is a major phenotype of clinical attack related to demyelinating neurological diseases of the central nervous system, including multiple sclerosis (MS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), and anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). As the concept of MOGAD is relatively new, the long-term visual outcomes after ON in MOGAD remains unclear.
Methods: To elucidate the long-term visual prognosis after ON in MOGAD, patients with MOGAD whose visual acuity were regularly followed for more than 5 years from the onset of ON were enrolled. Best-corrected visual acuity (BCVA) at nadir in the acute phase and at 1 and 5 years from onset was evaluated. The data from patients with MOGAD were compared with those from patients with MS or anti-AQP4-positive NMOSD.
Results: Twenty-three patients (31 ON-involved eyes) with MOGAD, 20 patients (24 ON-involved eyes) with MS, and 22 patients (24 ON-involved eyes) with anti-AQP4-positive NMOSD were evaluated. All BCVA at nadir, 1 year, and 5 years from the onset of ON were much worse in anti-AQP4-positive NMOSD than in MS (p = 0.0024) and MOGAD (p = 0.0014) patients. In MOGAD and anti-AQP4-positive NMOSD, the serum disease-specific antibody titer was not associated with the subsequent visual prognosis. Visual acuity had almost fully recovered spontaneously or shortly after initiating acute treatment in 22 of the 23 patients with MOGAD-ON. The administration of high-dose intravenous steroid therapy further facilitated early recovery of visual acuity. Meanwhile, a small fraction of patients with extensive optic nerve lesions involving the chiasma irreversibly experienced severe visual impairment despite appropriate acute treatment.
Conclusion: Although a small fraction of patients with MOGAD who presented with extensive optic nerve lesions experienced irreversible severe visual impairment, the long-term visual outcomes after 5 years from ON in patients with MOGAD were generally as good as that in patients with MS and much better than that in patients with anti-AQP4-positive NMOSD.
(Copyright © 2021. Published by Elsevier B.V.)
